1-(2-氨基-4-羟基-3-丙基苯基)乙烷-1-酮 | 87472-78-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-氨基-4-羟基-3-丙基苯基)乙烷-1-酮
• 英文名称: 2-amino-4-hydroxy-3-propylacetophenone
• 英文别名: 1-(2-Amino-4-hydroxy-3-propylphenyl)ethan-1-one；1-(2-amino-4-hydroxy-3-propylphenyl)ethanone
• CAS: 87472-78-4
• 化学式: C₁₁H₁₅NO₂
• mdl: MFCD00100406
• 分子量: 193.246
• InChiKey: DCWMBYCEMSKLFA-UHFFFAOYSA-N

物化性质

• 熔点：
  95 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi

反应信息

• 作为反应物：
  描述：

  1-(2-氨基-4-羟基-3-丙基苯基)乙烷-1-酮 在 lithium hydroxide 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 丙酮 为溶剂， 反应 4.0h， 生成 4-[(4-Acetyl-3-amino-2-propylphenoxy)methyl]-3-methoxybenzoic acid
  参考文献：
  名称：

  Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes

  摘要：

  Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group (e.g., the toluic acids 16 and 18). Although considerable attention has focused on FPL 55712-derived analogues, only limited investigations into alternatives for the standard 4-acetyl-3-hydroxy-2-propylphenoxy moiety have been reported. Therefore, an extensive study of modifications to the hydroxyacetophenone portion of toluic acid 18 was undertaken. Although no viable alternative to the 3-hydroxy moiety was discovered, replacements for the 2-propyl group (34, 37) and the 4-acetyl functionality (56, 59) yielded potent antagonists. A number of compounds exhibited longer duration of action in vivo than FPL 55712.

  DOI：

  10.1021/jm00124a014
• 作为产物：
  描述：

  2’-氨基-4’-甲氧基苯乙酮 在 palladium on activated charcoal 三氯化铝 、 氢气 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 丙酮 为溶剂， 25.0~200.0 ℃ 、206.84 kPa 条件下， 反应 42.0h， 生成 1-(2-氨基-4-羟基-3-丙基苯基)乙烷-1-酮
  参考文献：
  名称：

  Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes

  摘要：

  Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group (e.g., the toluic acids 16 and 18). Although considerable attention has focused on FPL 55712-derived analogues, only limited investigations into alternatives for the standard 4-acetyl-3-hydroxy-2-propylphenoxy moiety have been reported. Therefore, an extensive study of modifications to the hydroxyacetophenone portion of toluic acid 18 was undertaken. Although no viable alternative to the 3-hydroxy moiety was discovered, replacements for the 2-propyl group (34, 37) and the 4-acetyl functionality (56, 59) yielded potent antagonists. A number of compounds exhibited longer duration of action in vivo than FPL 55712.

  DOI：

  10.1021/jm00124a014

文献信息

• Anti-SRSA quinoline carboxylic acid derivatives
  申请人：Fisons plc

  公开号：US04474788A1

  公开（公告）日：1984-10-02

  There are described compounds of formula I, ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.7, which may be the same or different, each represent hydrogen, hydroxy, alkyl Cl to 6, alkoxy C1 to 6, amino, acyl C2 to 6, acylamino C2 to 6, alkenyl C2 to 6, halogen, or alkoxy C1 to 6 substituted by phenyl, X is a hydrocarbon chain of 1 to 10 carbon atoms optionally substituted by a hydroxy group, A is --Q--COOH, Q is absent or represents a straight or branched alkylene, alkenylene or alkynylene group of up to and including 6 carbon atoms, R.sub.8 and R.sub.9, which may be the same or different, each represent hydrogen or alkyl C1 to 6 or together form a single bond, D, Y and Z, which may be th same or different, each represent sulphur, oxygen or --NR.sub.10 --, and R.sub.10 is hydrogen or alkyl C1-C6, provided that (i) when D, Z and Y are all oxygen, R.sub.8 and R.sub.9 do not together form a single bond, (ii) when D is oxygen, R.sub.8 and R.sub.9 together form a single bond, X is (CH.sub.2).sub.5, A is --COOH, one of Y and Z is sulphur and the other is oxygen, at least one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.7 is other than hydrogen, and pharmaceutically acceptable salts, esters and amides thereof. There are also described processes to these compounds, and pharmaceutical, e.g. anti-allergic, compositions containing them.

  公式I的化合物已经描述如下，其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5和R.sub.7，它们可能相同也可能不同，每个代表氢、羟基、烷基Cl至6、烷氧基C1至6、氨基、酰基C2至6、酰胺基C2至6、烯烃基C2至6、卤素或被苯基取代的烷氧基C1至6，X是1至10个碳原子的烃链，可选择性地被羟基取代，A是--Q--COOH，Q为空缺或代表最多包括6个碳原子的直链或支链烷基、烯烃基或炔烃基，R.sub.8和R.sub.9，它们可能相同也可能不同，每个代表氢或烷基C1至6或一起形成单键，D、Y和Z，它们可能相同也可能不同，每个代表硫、氧或--NR.sub.10 --，R.sub.10是氢或烷基C1-C6，但要求(i)当D、Z和Y全部为氧时，R.sub.8和R.sub.9不得一起形成单键，(ii)当D为氧时，R.sub.8和R.sub.9一起形成单键，X为(CH.sub.2).sub.5，A为--COOH，Y和Z中的一个是硫，另一个是氧，R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5和R.sub.7中至少有一个不是氢，以及其药学上可接受的盐、酯和酰胺。还描述了这些化合物的过程，以及含有它们的药物，例如抗过敏剂组合物。
• Compounds and methods of treating cell proliferative diseases
  申请人：Leblanc Veronique

  公开号：US20050054629A1

  公开（公告）日：2005-03-10

  The present invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having anti-proliferative activities, as well as methods for treating various diseases associated with abnormal cell proliferation, including cancer, by administering said compounds. It further deals with pharmaceutical compositions comprising said compounds, more particularly useful to treat cancers.

  本发明涉及化合物及其用途，尤其是在制药业中的应用。本发明揭示了具有抗增殖活性的化合物，以及通过给予这些化合物来治疗与异常细胞增殖相关的各种疾病的方法，包括癌症。它进一步涉及包含这些化合物的制药组合物，更具体地用于治疗癌症。
• Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them
  申请人：FISONS plc

  公开号：EP0079637A1

  公开（公告）日：1983-05-25

  There are described compounds of formula I, in which R1, R2, R3, R4, Rs and R7,, which may be the same or different, each represent hydrogen, hydroxy, alkyl C1 to 6, alkoxy C 1 to 6, amino, acyl C2 to 6, acylamino C 2 to 6, alkenyl C 2 to 6, halogen, or alkoxy C 1 to 6 substituted by phenyl, X is a hydrocarbon chain of 1 to 10 carbon atoms optionally substituted by a hydroxy group, A is -Q-COOH, 0 is absent or represents a straight or branched alkylene, alkenylene or alkynylene group of up to and including 6 carbon atoms, R8 and Rs, which may be the same or different, each represent hydrogen or alkyl C 1 to 6 or together form a single bond, D, Y and Z, which may be the same or different, each represent sulphur, oxygen or -NR,o-, and R10 is hydrogen or alkyl C1-C6, provided that i) when D, Z and Y are all oxygen, RB and R9 do not together form a single bond, ii) when D is oxygen, R8 and R9 together form a single bond, X is (CH2)5, A is -COOH, one of Y and Z is sulphur and the other is oxygen, at least one of R1, R2, R3, R4, R5 and R7 is other than hydrogen, and pharmaceutically acceptable salts, esters and amides thereof. There are also described processes to these compounds, and pharmaceutical, e.g. anti-allergic, compositions containing them.

  所述化合物为式 I、 其中 R1、R2、R3、R4、Rs 和 R7（可以相同或不同）分别代表氢、羟基、C1 至 6 烷基、C1 至 6 烷氧基、氨基、C2 至 6酰基、C2 至 6酰氨基、C2 至 6烯基、卤素或被苯基取代的 C1 至 6 烷氧基、 X 是任选被羟基取代的 1 至 10 个碳原子的烃链、 A 是-Q-COOH、 0 不存在或代表直链或支链烯基、炔基或炔烃基，最多包括 6 个碳原子、 R8 和 Rs 可以相同或不同，各自代表氢或 C 1-6 烷基，或共同形成单键、 D、Y 和 Z（可以相同或不同）各自代表硫、氧或-NR,o-，以及 R10 是氢或 C1-C6 烷基、 条件是 i) 当 D、Z 和 Y 都是氧时，RB 和 R9 不能一起形成单键、 ii) 当 D 是氧时，R8 和 R9 一起形成单键，X 是 (CH2)5，A 是 -COOH，Y 和 Z 中的一个是硫，另一个是氧，R1、R2、R3、R4、R5 和 R7 中至少有一个不是氢、 及其药学上可接受的盐、酯和酰胺。 此外，还介绍了这些化合物的加工工艺，以及含有这些化合物的药物组合物，例如抗过敏组合物。
• BROWN, FREDERICK J.;BERNSTEIN, PETER R.;CRONK, LAURA A.;DOSSET, DAVID L.;+, J. MED. CHEM., 32,(1989) N, C. 807-826
  作者：BROWN, FREDERICK J.、BERNSTEIN, PETER R.、CRONK, LAURA A.、DOSSET, DAVID L.、+

  DOI：——

  日期：——
• COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES
  申请人：Exonhit Therapeutics S.A.

  公开号：EP1480966A1

  公开（公告）日：2004-12-01